跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
連結會在新分頁中打開
English
中文
在 臺北醫學大學 搜尋內容
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
查看斯高帕斯 (Scopus) 概要
劉 明哲
合聘副教授
,
臨床醫學研究所
主治醫師
,
臺北醫學大學附設醫院
副主任
,
臺北醫學大學器官移植研究中心
成員
,
臺北醫學大學泌尿腎臟研究中心
教授
,
牙體技術學系
成員
,
臺北醫學大學生醫器材研究中心
https://orcid.org/0000-0001-5127-7593
電子郵件
d204097002
tmu.edu
tw
h-index
785
引文
17
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2026
每年研究成果
概覽
指紋
網路
專案
(5)
研究成果
(44)
類似的個人檔案
(6)
指紋
查看啟用 Ming-Che Liu 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
70%
Immunogenicity
64%
SARS Coronavirus
64%
Placebo
64%
Bladder Cancer
62%
Neoplasm
59%
Castration Resistant Prostate Cancer
43%
Randomized Controlled Trial
43%
Catenin
43%
Inflammation
43%
Cisplatin
34%
Adverse Event
31%
Antidiabetic Agent
28%
Cancer Growth
28%
Tolerability
27%
Sonic Hedgehog Protein
26%
Human Papillomavirus Type 16
25%
Protein Kinase B
23%
22 Oxacalcitriol
21%
Chronic Kidney Failure
21%
Aluminum Hydroxide
21%
Pharmacodynamic Modeling
21%
Ovary Cancer
21%
Electrolyte Solution
21%
Diterpenoid
21%
Hernia
21%
Bladder Carcinogenesis
21%
microRNA
21%
Inguinal Hernia
21%
Hedgehog
21%
Liver Cancer
21%
Muscle Invasive Bladder Cancer
21%
Erectile Dysfunction
21%
Vismodegib
21%
Hyaluronic Acid
21%
Lipopolysaccharide
21%
Fibrinolytic Agent
21%
Nanoclusters
21%
Protein Vaccine
21%
Secondary Hyperparathyroidism
21%
Diabetes Mellitus
21%
Hemodialysis
21%
Trigonelline
21%
Thrombus
21%
Shock Wave
21%
Cardiovascular Disease
21%
Carbohydrates
21%
Functional Food
21%
Cordyceps
21%
Diabetic Nephropathy
21%
Immunology and Microbiology
Immunogenicity
100%
Severe Acute Respiratory Syndrome Coronavirus 2
89%
COVID-19
60%
Antibody Response
48%
Seroconversion
36%
Infectious Disease
34%
Infection
34%
Humoral Immunity
30%
B Cell
30%
Spike
26%
Cancer Cell
26%
Cytokine
25%
Normal Human
25%
Adoptive Immunity
25%
Neutralizing Antibody
23%
Cell Line
23%
Cancer Associated Fibroblast
21%
Omicron Coronavirus Variant
21%
Tumor-Associated Macrophage
21%
Hemodialysis
21%
Mesenchymal Stem Cell
21%
Endurance Training
21%
Influenza Vaccine
21%
Humoral Antibody
21%
Osteoarthritis
21%
Catenin
21%
Human Immunodeficiency Virus
21%
down Regulation
21%
Cancer Stem Cell
21%
Muscle
21%
Signal Transduction
21%
Autophagy
21%
Antiviral Activity
21%
Tissue Regeneration
21%
Intervertebral Disk
21%
Nucleus Pulposus
21%
Antigen
17%
Receptor Binding
17%
Vaccine Efficacy
16%
Hemagglutinin
16%
Immune Response
15%
Platelet-Rich Plasma
12%
High Risk Population
12%
CD4 CD8 Ratio
11%
Platelet Count
10%
Influenza
10%
Antibody Titer
10%
Secretory Immunoglobulin
10%
Fenugreek
10%
Fibroblast
10%
Medicine and Dentistry
Erectile Dysfunction
43%
Hedgehog Signaling
43%
Thrombocyte Rich Plasma
43%
Adverse Event
28%
Placebo
28%
Kidney Function
26%
Stem Cell
26%
Sonic Hedgehog Protein
26%
Cancer Growth
23%
Neoplasm
23%
Immunogenicity
21%
Randomized Controlled Trial
21%
Ingestion
21%
Electrolyte Solution
21%
Endurance Training
21%
Extracorporeal Shock Wave Lithotripsy
21%
Ureter Stone
21%
Oxidative Stress
21%
Muscle Invasive Bladder Cancer
21%
Diabetic Nephropathy
21%
Influenza Vaccine
21%
Vismodegib
21%
Osteoporosis
21%
Castration Resistant Prostate Cancer
21%
Shock Wave
21%
Bone Regeneration
21%
Extracorporeal Shockwave Therapy
21%
Cordyceps
21%
Seminal Vesicle
21%
Carbohydrates
21%
Adverse Outcome
21%
Frailty
21%
Magnetic Resonance Imaging
21%
Agenesis
21%
Vas Deferens
21%
Urologic Surgery
21%
Extracorporeal
21%
Hemagglutinin
21%
Retrospective Cohort Study
21%
Severe Acute Respiratory Syndrome Coronavirus 2
21%
COVID-19
21%
Antiviral Activity
21%
Small Interfering RNA
21%
Antigen
17%
Postoperative Complication
17%
Influenza
16%
Blood Glucose
14%
Hyperglycemia
14%
Biocompatible Material
14%
Hazard Ratio
14%
